Document Detail


High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.
MedLine Citation:
PMID:  18182077     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: In multiple myeloma (MM) YKL-40 is present in the bone marrow microenvironment and is suggested to play a role in remodelling of the extracellular matrix. Here, the association between serum YKL-40 and severity of bone disease in MM is investigated. METHODS: Serum YKL-40 was measured in 34 MM patients at diagnosis. Bone disease was assessed by radiography and biochemical markers of bone metabolism. Patients were treated with conventional chemotherapy and followed for up to 30 months. RESULTS: Patients with a serum YKL-40 elevated above the age specific reference range (56%) had a higher total X-ray score (P = 0.003) and higher levels of the markers of bone resorption serum C-terminal telopeptide of collagen type I (P = 0.003), urine pyridinoline (P = 0.04) and urine deoxypyridinoline (P = 0.002), while the levels of urine N-terminal telopeptide of collagen type I (NTX-1) and the markers of bone formation equalled those seen in patients with a normal serum YKL-40. Serum YKL-40 level (beta = 7.6; P = 0.002) and urine NTX-1 (log(2)) (beta = 3.5; P = 0.006) were independent predictors of total X-ray score at diagnosis. Patients with elevated serum YKL-40 at diagnosis had shorter time to first osteolytic event compared to patients with normal serum YKL-40 (12 months vs. not reached; Log rank test: P = 0.03). CONCLUSIONS: Newly diagnosed MM patients with elevated serum concentrations of YKL-40 have more severe bone destruction including increased bone resorptive activity and shorter time to progression of bone disease. At this point, a potential role for YKL-40 in myeloma-related bone disease must be considered.
Authors:
Anne K Mylin; Niels Abildgaard; Julia S Johansen; Niels F Andersen; Lene Heickendorff; Therese Standal; Peter Gimsing; Lene M Knudsen
Related Documents :
12457407 - Spectrum of dolichospondylic dysplasia: two new patients with distinctive findings.
8255797 - Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21.
21298757 - Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with...
6836227 - Haematopoietic progenitors in essential thrombocythaemia.
20551097 - Characteristics of joint involvement and relationships with systemic inflammation in sy...
21946897 - Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-12-21
Journal Detail:
Title:  European journal of haematology     Volume:  80     ISSN:  1600-0609     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-07     Completed Date:  2008-03-24     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  310-7     Citation Subset:  IM    
Affiliation:
Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. anne.k.mylin@dadlnet.dk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Biological Markers / blood
Bone Diseases / blood*,  complications,  pathology*,  radiography
Disease Progression
Female
Glycoproteins / blood*
Humans
Lectins
Male
Middle Aged
Multiple Myeloma / blood*,  complications,  diagnosis*
Serum / metabolism*
Survival Rate
Chemical
Reg. No./Substance:
0/Biological Markers; 0/CHI3L1 protein, human; 0/Glycoproteins; 0/Lectins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genotype by environment interactions for fitness in hybrid genotypes of Avena barbata.
Next Document:  Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical...